Covered recipient · General Payments record
LEON KIRCIK
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$398,455.32
241 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $149,836.25 | 46 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,545.10 | 55 |
| Honoraria | $81,850.00 | 23 |
| Travel and Lodging | $19,573.54 | 46 |
| Food and Beverage | $4,650.43 | 71 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | $82,773.48 | 48 |
| Almirall LLC | $79,050.25 | 30 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $66,439.40 | 43 |
| Lilly USA, LLC | $47,215.67 | 39 |
| Novartis Pharmaceuticals Corporation | $31,823.70 | 17 |
| UCB, Inc. | $21,366.05 | 15 |
| Amgen Inc. | $15,886.50 | 6 |
| LEO Pharma Inc. | $13,400.79 | 7 |
| Incyte Corporation | $10,085.76 | 9 |
| PFIZER INC. | $7,300.00 | 2 |
| VYNE Pharmaceuticals Inc. | $5,536.80 | 5 |
| EPI Health, LLC | $5,401.57 | 6 |
| E.R. Squibb & Sons, L.L.C. | $4,187.65 | 5 |
| Taro Pharmaceuticals USA, Inc. | $3,750.00 | 5 |
| Eli Lilly and Company | $3,500.00 | 1 |
| Mindera Corp | $650.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $65.77 | 1 |
| Galderma Laboratories, L.P. | $21.93 | 1 |
Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LEON KIRCIK
NPI 1760576599 · CMS profile ID 171344
Allopathic & Osteopathic Physicians / Dermatology
LOUSIVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LEON KIRCIK, NPI 1760576599, CMS profile ID 171344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). LEON KIRCIK, NPI 1760576599, CMS profile ID 171344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- LEON KIRCIK, NPI 1760576599, CMS profile ID 171344, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
241 matching records · $398,455.32 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 241.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $3,738.00 | 09/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826381261 | CMS |
| Novartis Pharmaceuticals Corporation | $2,280.00 | 09/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752845 | CMS |
| Novartis Pharmaceuticals Corporation | $86.46 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752863 | CMS |
| UCB, Inc. | $1,600.00 | 09/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807426749 | CMS |
| UCB, Inc. | $2,130.00 | 09/13/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288281 | CMS |
| Amgen Inc. | $3,738.00 | 09/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826381263 | CMS |
| Lilly USA, LLC | $2,450.00 | 09/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818595781 | CMS |
| Lilly USA, LLC | $2,800.00 | 09/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818657111 | CMS |
| Taro Pharmaceuticals USA, Inc. | $500.00 | 09/10/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851408869 | CMS |
| LEO Pharma Inc. | $6,580.00 | 09/09/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842215309 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $5,600.00 | 09/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849558943 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $282.80 | 09/09/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849558947 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $411.60 | 09/09/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849558951 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $91.18 | 09/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849558953 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $750.00 | 09/07/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849558899 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,050.00 | 09/07/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559023 | CMS |
| Almirall LLC | $296.84 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696477 | CMS |
| EPI Health, LLC | $75.47 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854625371 | CMS |
| Almirall LLC | $193.10 | 08/25/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696473 | CMS |
| Almirall LLC | $153.85 | 08/25/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696475 | CMS |
| Almirall LLC | $104.65 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696479 | CMS |
| Lilly USA, LLC | $22.66 | 08/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818657109 | CMS |
| LEO Pharma Inc. | $24.81 | 08/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842215297 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $4,200.00 | 08/20/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559005 | CMS |
| PFIZER INC. | $3,900.00 | 08/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832935107 | CMS |
| Almirall LLC | $2,400.00 | 08/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696471 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 08/18/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851903921 | CMS |
| Almirall LLC | $55.73 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965162951 | CMS |
| Novartis Pharmaceuticals Corporation | $2,280.00 | 08/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752843 | CMS |
| Almirall LLC | $95.55 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965162949 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,400.00 | 08/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559055 | CMS |
| Incyte Corporation | $93.52 | 08/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835527445 | CMS |
| LEO Pharma Inc. | $17.88 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842215287 | CMS |
| UCB, Inc. | $114.58 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807390269 | CMS |
| UCB, Inc. | $53.63 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807393743 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 08/05/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851903963 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,200.00 | 08/05/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851903965 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $64.18 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851903969 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $260.10 | 08/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559001 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $315.00 | 08/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559009 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $26.95 | 08/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559014 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $46.00 | 08/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849559017 | CMS |
| Almirall LLC | $420.80 | 07/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696465 | CMS |
| Almirall LLC | $490.09 | 07/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819696467 | CMS |
| Lilly USA, LLC | $2,800.00 | 07/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818657107 | CMS |
| Lilly USA, LLC | $2,800.00 | 07/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818583789 | CMS |
| Lilly USA, LLC | $2,450.00 | 07/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818595779 | CMS |
| Lilly USA, LLC | $423.05 | 07/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818603929 | CMS |
| Lilly USA, LLC | $12.30 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818627391 | CMS |
| Lilly USA, LLC | $840.34 | 07/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818640003 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $64,240.70 | 2 |
| PY2025 | Principal investigator | $650,441.82 | 71 |
| PY2024 | Recipient | $331,871.61 | 14 |
| PY2024 | Principal investigator | $993,759.40 | 303 |
| PY2023 | Recipient | $361,872.20 | 8 |
| PY2023 | Principal investigator | $611,255.57 | 264 |
| PY2022 | Recipient | $355.00 | 2 |
| PY2022 | Principal investigator | $354,096.53 | 54 |
| PY2021 | Recipient | $147,270.27 | 8 |
| PY2021 | Principal investigator | $540,488.16 | 81 |
| PY2020 | Recipient | $313,697.33 | 9 |
| PY2020 | Principal investigator | $1,160,244.93 | 110 |
| PY2019 | Recipient | $109,851.67 | 9 |
| PY2019 | Principal investigator | $1,195,018.99 | 104 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
73 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,964.41 | 12/22/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,907.00 | 12/15/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,249.00 | 12/15/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412594 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,794.00 | 12/15/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112178 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,630.00 | 12/09/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289378 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 12/09/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289380 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,400.00 | 12/09/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289382 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,486.00 | 12/08/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112160 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65,773.00 | 12/08/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226112167 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,045.60 | 12/01/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289029 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,500.43 | 11/17/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112153 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $625.00 | 11/04/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,296.00 | 10/27/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412544 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,937.00 | 10/27/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112140 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,726.68 | 10/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112128 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 10/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112135 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,460.60 | 09/25/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285903 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,592.00 | 09/22/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412549 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,974.78 | 09/15/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112117 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,314.00 | 09/08/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,296.00 | 09/01/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412600 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 08/15/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240591233 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,222.29 | 08/11/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112104 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,256.00 | 08/11/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112111 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,681.00 | 08/04/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112100 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,638.40 | 08/01/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283669 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,156.20 | 08/01/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283671 |
| Recipient | PFIZER INC. | $3,200.00 | 07/31/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802936 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,062.00 | 07/28/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412578 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,690.10 | 07/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226112082 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,818.00 | 07/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112090 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,820.32 | 07/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112094 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,861.30 | 07/08/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,941.00 | 06/30/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,657.92 | 06/16/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112054 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,405.40 | 06/16/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226112059 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,705.00 | 06/16/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112065 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,046.00 | 06/09/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,318.00 | 05/26/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412564 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,945.05 | 05/20/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279974 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,337.00 | 05/19/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112072 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,567.13 | 05/19/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112076 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,335.30 | 05/12/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226112037 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $22,539.00 | 05/05/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,858.00 | 04/28/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412539 |
| Principal investigator 1 | Incyte Corporation | $1,975.14 | 04/25/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240591229 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,080.00 | 04/14/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112019 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,802.61 | 04/07/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112006 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,135.30 | 04/07/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226112015 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,996.80 | 04/03/2025 | Non-covered Recipient Entity Physicians Skin Care, PLLC | A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) | No dispute reported | 06/30/2026 | 1235994676 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,836.00 | 04/02/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111988 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,000.00 | 03/25/2025 | Non-covered Recipient Entity Skin Sciences PLLC Leon Kircik | Speso moderate to severe HS Phase IIb/III | No dispute reported | 06/30/2026 | 1220791725 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,550.00 | 03/25/2025 | Non-covered Recipient Entity Skin Sciences PLLC Leon Kircik | Speso moderate to severe HS Phase IIb/III | No dispute reported | 06/30/2026 | 1220791727 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,765.00 | 03/24/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412589 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,042.00 | 03/24/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111983 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,813.83 | 03/17/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112001 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,131.39 | 03/14/2025 | Non-covered Recipient Entity Skin Sciences, Pllc | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235993663 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,714.00 | 03/10/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226111994 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $25,563.00 | 03/04/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111974 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,809.75 | 03/04/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,737.00 | 03/03/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412556 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,856.16 | 02/24/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112012 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,425.00 | 02/21/2025 | Non-covered Recipient Entity Skin Sciences | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235993665 |
| Principal investigator 1 | Eli Lilly and Company | $2,500.00 | 02/13/2025 | Non-covered Recipient Entity SKIN SCIENCES, PLLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187888270 |
| Recipient | LEO Pharma Inc. | $61,040.70 | 02/06/2025 | Covered Recipient Physician | THE SAFETY AND EFFICACY OF ADBRY IN SKIN OF COLOR PATIENTS WITH ATOPIC DERMATITIS IN THE REAL-WORLD SETTING | No dispute reported | 06/30/2026 | 1251994450 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,942.82 | 02/04/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226111967 |
| Principal investigator 1 | Incyte Corporation | $2,335.71 | 01/28/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240477124 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $173.06 | 01/27/2025 | Non-covered Recipient Entity Skin Sciences | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235993667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,777.00 | 01/27/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175412582 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,675.78 | 01/21/2025 | Non-covered Recipient Entity Skin Sciences | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235993669 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,860.00 | 01/21/2025 | Non-covered Recipient Entity Leon Kircik Md Skin Sciences Pllc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111978 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,346.20 | 01/21/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274263 |
| Principal investigator 1 | Incyte Corporation | $3,266.36 | 01/17/2025 | Non-covered Recipient Entity SKIN SCIENCES PLLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240591224 |